Lineage Cell Therapeutics, Inc. LCTX
Regular-session close
After hours · Nov 19, 4:18 PM ET
- YTD
- -50.90%
- 1 year
- -52.05%
- Market cap
- 207.42M
- Revenue (ttm)
- 6.19M
- EPS (ttm)
- -0.09
- Shares out
- 220.42M
- Forward P/E
- -3.66
- YTD return
- -50.90%
- 1-year return
- -52.05%
- 50-day average
- 0.7364
- Volume
- 1.31M
- Avg volume
- 1.63M
- Open
- 0.8366
- Previous close
- 0.8385
- Day's range
- 0.82 – 0.85
- 52-week range
- 0.77 – 1.99
- Beta
- 1.28
- Price target
- 4.83 (+489.4%)
Key statistics
- 200-day average
- 0.96025
- Enterprise value
- 130.15M
- Price / sales
- 19.54
- Price / book
- 1.52
- Revenue growth
- -56.30%
- Free cash flow
- -8.91M
- Total cash
- 38.50M
- Total debt
- 2.95M
- Return on equity
- -35.04%
- Short % of float
- 10.89%
Fundamental scorecard
9 of 25 checks passed on LCTX’s reported financials
9of 25 checks passed
- Value 1 of 5
- Growth 3 of 5
- Profitability 2 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.04 | -0.02 | +0.02 | +50.00% |
| Aug 8, 2024 | Jun 1, 2024 | -0.04 | -0.03 | +0.01 | +25.00% |
| May 9, 2024 | Mar 1, 2024 | -0.04 | -0.04 | 0.00 | 0.00% |
| Mar 7, 2024 | Dec 1, 2023 | -0.07 | -0.03 | +0.04 | +57.14% |
| Nov 9, 2023 | Sep 1, 2023 | -0.04 | -0.04 | 0.00 | 0.00% |
| Aug 10, 2023 | Jun 1, 2023 | -0.04 | -0.03 | +0.01 | +25.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 4, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 20, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 18, 2024 | D. Boral Capital | init | — | Buy |
| Aug 20, 2024 | Craig-Hallum | init | — | Buy |
| May 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 8, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- lineagecell.com
News
What Lineage Cell Therapeutics (LCTX) Said on Its Q3 Earnings Call
Lineage Cell Therapeutics, Inc. (LCTX) Q3 2026 Earnings Call Transcript
Lineage Cell (LCTX) Reports Q3 Loss, Misses Revenue Estimates Lineage Acquires NeuroAirmid Therapeutics
Lineage Cell Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Lineage Announces Acquisition of NeuroAirmid Therapeutics and Clinical Stage Program for the Treatment of Huntington's Disease
Your note
Sign in to keep a note on LCTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAILEY DON MATTHEW | Director | Purchase | Feb 7, 2024 | 0 |
| BROADWOOD PARTNERS, L.P. | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 5, 2024 | 83,420,100 |
| CULLEY BRIAN M | Chief Executive Officer | Purchase | Nov 20, 2024 | 194,842 |
| HOGGE GARY S | Officer | Conversion of Exercise of derivative security | Feb 9, 2023 | 7,710 |
| HOWE JILL ANN | Chief Financial Officer | Purchase | Nov 25, 2024 | 25,500 |
| JAYASURIYA ANULA | Director | Purchase | Dec 28, 2023 | 10,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Broadwood Capital, Inc. | 18.90% | 41,666,255 | 22.85M | Sep 29, 2024 |
| Blackrock Inc. | 4.50% | 9,919,800 | 5.44M | Sep 29, 2024 |
| Vanguard Group Inc | 3.90% | 8,600,995 | 4.72M | Sep 29, 2024 |
| Defender Capital, LLC | 2.27% | 5,002,198 | 2.74M | Sep 29, 2024 |
| Logos Global Management LP | 2.27% | 5,000,000 | 2.74M | Sep 29, 2024 |
| Raffles Associates Lp | 2.05% | 4,507,781 | 2.47M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.00% | 4,416,552 | 2.42M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.67% | 3,684,588 | 2.02M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.28% | 2,814,846 | 1.54M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.69% | 1,525,311 | 836.63K | Aug 30, 2024 |
| iShares Russell 2000 Growth ETF | 0.59% | 1,305,502 | 716.07K | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.49% | 1,075,956 | 590.16K | Oct 30, 2024 |
